Pre Formulation Studies Solubility & Stability Analysis - Part 1

Main ideas and lessons (Pre-formulation: Solubility & Stability)

Purpose of pre-formulation studies (“learning before doing”)

Pre-formulation studies aim to:

• Establish the physicochemical properties of a new (or known) drug entity.
• Determine kinetics and stability.
• Assess compatibility with excipients/ingredients used in formulations (e.g., dissolution/permeation enhancers, solvents/water).
• Identify whether the drug/excipient system is degrading or chemically compatible.
• Use stability insights to define proper processing and storage conditions that maintain quality through shelf life.

Why solubility and stability matter

• Stability

  • Controls chemical integrity of the therapeutic ingredient.
  • Considered for both:
    • In vivo stability (what happens in the body)
    • In vitro stability (during formulation/storage/usage conditions)
  • Degradation can generate byproducts:
    • If byproducts are non-toxic/neutral → generally acceptable.
    • If byproducts have side effects → may require dose modification/reduction.

• Solubility

  • Directly impacts bioavailability (rate and extent of drug becoming available in the body).
  • Inadequate solubility can lead to poor absorption and reduced therapeutic efficiency.

• Combined impact

  • Both help anticipate obstacles during formulation and storage, including industrial processing conditions.

---

Key definitions and concepts

Shelf life (stability concept)

• Shelf life = the time during which the drug remains stable.
• Often defined as the time until 10% of the drug degrades.
• After expiry (even if not “unsafe”), the dosage form should not be used.

Solubility (solubility concept)

• Solubility = maximum amount of solute that can dissolve in a solvent at a given temperature and pressure.
• General trends:
  • Higher temperature → higher solubility
  • Lower temperature → lower solubility

Saturation solubility (Cs)

• Saturation solubility (Cs) is the point at which no more drug can enter the solvent under specified conditions.

Pharmacopoeial solubility categories (qualitative classification)

Classifications are based on how many parts of solvent are needed to dissolve 1 part of solute:

• Very soluble: < 1 part solvent
• Freely soluble: 1–10 parts solvent
• Soluble: 10–30 parts solvent
• Practically insoluble: > 10,000 parts solvent

Example mg/mL practical thresholds (as given):

• > 1000 mg/mL → very soluble
• 100–1000 mg/mL → freely soluble
• (Other related categories follow standard ranges.)

Absolute vs intrinsic solubility

• Intrinsic solubility concept: solubility of the unionized (non-ionized) form at 37°C.
• For ionizable drugs, intrinsic solubility is tied to the unionized form (or relevant ion form depending on context).
• Determination environments may include:
  • Neutral, acidic, alkaline media
  • Examples: 0.1 M HCl, water, 0.1 M NaOH
• Typical temperatures: 4°C, 25°C, 37°C, up to 50°C (depending on processing conditions).

---

Methodology / instruction-style steps described

A) Solubility analysis workflow (implied methodology)

• Select conditions relevant to clinical/physiological contexts:
  • Use appropriate temperature and pressure.
• Determine intrinsic solubility:
  • Measure in multiple media (acidic/neutral/alkaline).
  • Use representative solutions such as:
    • 0.1 M HCl, water, 0.1 M NaOH
  • Test across relevant temperatures (including 37°C).
• Use results to choose formulation solvents/buffers:
  • Decide suitable buffer media or pure solvents for development.
• Predict in vivo performance using intrinsic solubility:
  • Example: if a drug is insoluble at pH 1.2 (stomach), an immediate-release formulation may fail due to inadequate dissolution/absorption.

B) Molecular dissociation / pKa determination approach

• Identify ionizable drugs (susceptible to ionization changes).
• Apply Henderson–Hasselbalch concepts to relate pH and ionization.
• Determine:
  • pKa (for weak acids): relates pH to protonated vs unionized ratio
  • pKb (for bases) and related constants
• pKa interpretation concept:
  • pKa is the pH where 50% is ionized and 50% is unionized.

pKa determination techniques listed

• Potentiometry
• UV spectrophotometry
• Solubility methods
• HPLC
• Capillary zone electrophoresis
• Foaming activity (mentioned in the subtitle list)

Formulation and dosing implications

• For oral drugs, GI pH varies approximately from 1.2 to 6.8, then around 7.1–7.2.
• Choose formulation pH/solubilization conditions to favor the most beneficial ionization state.
• Consider counter-ion effects:
  • Chloride/hydrochloride salts can significantly affect solubility and ionization behavior.
• Extend studies beyond water:
  • Measure in non-aqueous solvents (often co-solvents), especially for:
    • topicals/liniments
    • oily injections
• Use solvent solubility data to guide manufacturing:
  • Wet granulation → typically uses aqueous solvents
  • Dry granulation → avoids aqueous; uses non-aqueous solvents

C) Solubility rate / dissolution study methodology (implied steps)

• Goal: determine how fast the drug dissolves in relevant media.
• Factors to control/consider:
  • Particle size and particle size distribution
    • Smaller particles → larger surface area → faster dissolution
    • Mixed sizes can alter dissolution behavior
  • Wettability of the particle surface
  • Dissolution fluid properties
    • polarity and rheology (e.g., thicker media slow dissolution)
  • Agitation/stirring method
    • often start with paddle apparatus (USP), then adjust using other USP apparatus types
  • Maintain temperature (e.g., 37°C) and select pH consistent with dissociation/solubility behavior.
• Use dissolution data to design dosage form release profiles:
  • Immediate-release vs sustained-release require different dissolution rate expectations.
• Validate against available pharmacopoeial/reference standards if possible.

D) Diffusion study methodology / factors (conceptual)

After dissolution, drug must diffuse through biological fluids and across membranes.

Key factors affecting diffusion rate:

• Viscosity of the medium
• Temperature
• Concentration gradient (driving force)
• Surface area (larger surface area → more diffusion)

In vitro flexibility:

• Temperature can be varied in vitro to observe effects.

E) Partition coefficient determination and application

• Goal: estimate drug lipophilicity and partitioning between oil-like and water-like phases.
• Partition coefficient concept:
  • ratio of concentration in the oil phase to that in the water phase at equilibrium.

Experimental setup described

• Use octanol as a model lipid phase.
• Mix known drug concentration with known volumes of:
  • octanol and water
• Shake until equilibrium is reached.
• Sample and measure drug distribution (aqueous vs octanol).

Formulation decisions

• Lipophilic drugs may cross membranes, but still require sufficient solubility to work.
• Balance is needed between:
  • ability to cross membranes
  • ability to dissolve

F) Permeability testing methodology (diffusion cell concept)

• Goal: determine how well the drug permeates biological membranes.
• Method:
  • Use a two-compartment diffusion cell separated by a semi-permeable membrane
  • Place formulation/drug in the top compartment
  • Fill the bottom compartment with physiological fluid (examples: normal saline or pH 1.2)
  • Measure drug permeating over time → permeability/transport rate

Factors affecting permeability:

• Solubility and partition coefficient
• Diffusion coefficient
• Membrane properties (and relevance to biological tissue)
• Fluid properties: viscosity, density, temperature

---

Biopharmaceutics Classification System (BCS): the 4-class framework

• Based on solubility and permeability (measured experimentally).
• Proposed by Amidon.

Classes

• Class 1: High solubility + High permeability
• Class 2: High permeability + Low solubility
• Class 3: Low permeability + High solubility
• Class 4: Low solubility + Low permeability

Formulation implications mentioned

• Class 1
  • Well absorbed → suitable for immediate-release formulations.
• Class 2
  • Bioavailability limited by solubilization rate (low solubility).
  • Improving solubility can improve bioavailability.
  • Mentions need for in vivo/in vitro correlation.
• Class 3
  • Limited by permeation (low permeability).
  • Strategies: permeation enhancement approaches / improve GI transit time.
• Class 4
  • Poorly bioavailable → not reliably absorbed; high variability.

Important cautions

• BCS classification is an estimate, not a definitive guarantee of bioavailability.
• Oral bioavailability is influenced by:
  • in vivo stability
  • metabolism
  • transport mechanisms (efflux and absorptive transporters)
  • additional pharmacokinetic factors mentioned (e.g., glomerular filtration rate, compartment movement/receptors)

---

Additional physical/solid-state considerations

Hygroscopicity / moisture uptake

• Highly hygroscopic drugs may be unsuitable for certain solid dosage forms.
• Effects:
  • packaging requirements
  • microbial growth expectations
  • selection of solvents for solubilization

Polymorphism and crystalline character

• Solubilization depends on:
  • polymorphic/crystalline form
  • how solvent selection changes which polymorph interacts/dissolves
• Therefore, these characteristics should be studied before selecting solvents and formulation strategy.

---

Takeaway (explicit conclusion)

Understanding drug solubilization characteristics is essential for:

• choosing the right solvent
• developing a formulation that is stable and bioavailable
• ensuring route-of-administration compatibility
• supporting industrial manufacturing/process decisions

BCS classification (solubility + permeability) helps anticipate formulation behavior and guide drug development.

---

Speakers / sources featured

• Speaker(s): not explicitly named in the subtitles (delivered by an unnamed instructor/voice).
• Named sources/framework contributors:
  • Amidon (proposed BCS)
  • FDA (regulatory basis mentioned for bioequivalence studies)
  • Pharmacopoeia / USP (reference standards and dissolution apparatus guidance)